查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1974190

碳-13市場：按純度、應用和最終用戶分類 - 2026-2032年全球預測

Carbon-13 Market by Purity Level, Application, End-User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，碳-13 市場價值將達到 3,942 萬美元，到 2026 年將成長到 4,415 萬美元，到 2032 年將達到 6,353 萬美元，複合年成長率為 7.05%。

主要市場統計數據
基準年 2025 3942萬美元
預計年份：2026年 4415萬美元
預測年份 2032 6353萬美元
複合年成長率 (%) 7.05%

本文簡要解釋了碳-13在分析、臨床和工業應用中的戰略重要性，以及組織為何需要重新評估其採購和研發重點。

碳-13在分析科學、臨床研究和工業監測中發揮著至關重要的作用，它是光譜學、成像和示踪研究的重要穩定同位素。隨著實驗室和診所不斷擴展富集同位素的應用範圍，了解其供應特性、純度規格和主導需求已成為採購經理和技術團隊的策略重點。該同位素特異性的核特性使其能夠用於高解析度核磁共振研究、臨床試驗中的靶向代謝成像以及高靈敏度的環境追蹤，但要全面實現這些目標，需要一套完善的採購和品質保證方法。

技術創新、監管完善和跨學科合作正在共同重新定義碳-13應用領域的供應鏈、品質期望和創新路徑。

近年來，由於技術進步、監管改善和跨學科應用等因素的共同作用，碳-13領域正在經歷變革。富集技術和標記化學的突破提高了產品的特異性，並拓展了其應用範圍，從而重塑了對科學研究機構和臨床應用的需求。同時，監管機構和倫理審查委員會也加強了對臨床級材料和可追溯性的審查，迫使供應商實施更嚴格的文件記錄和品管方法。

對美國 2025 年實施的關稅變化對營運、採購和供應鏈產生的連鎖影響進行評估，並探討應對這些影響的策略措施。

美國將於2025年實施的關稅調整產生了一系列營運和戰略影響，需要整個碳-13價值鏈上的相關人員認真考慮。短期內，籌資策略已發生轉變，採購團隊重新評估了供應商組合，以應對不斷上漲的到岸成本和日益複雜的合規要求。因此，各組織加快了對替代供應商的認證，優先考慮與穩定合作夥伴簽訂長期契約，並加強了對總擁有成本（TCO）的審查，以保持預算的可預測性。

可操作的細分資訊，闡明純度閾值和特定應用要求如何影響採購決策、認證通訊協定和技術性能預期。

市場細分為解讀碳-13生態系統中的需求促進因素和技術要求提供了至關重要的背景資訊。根據純度水平，市場分析將產品分為「低於99%」和「高於99%」兩類。這種區分至關重要，因為高靈敏度分析方法和符合監管要求的臨床工作流程通常需要高純度材料。因此，實驗室和臨床機構的採購團隊在需要純度高於99%的材料時，通常會採用嚴格的合格通訊協定；而在研究機構中，如果成本效益是首要考慮因素，則可接受純度低於99%的材料用於探索性分析。

決定供應韌性、監管合規性和夥伴關係策略的區域動態和營運現實在美洲、歐洲、中東和非洲以及亞太地區各不相同。

區域趨勢影響各組織如何保障物資供應、管理物流以及因應法規結構。在美洲，成熟的研究機構和臨床網路構成了集中的需求中心，這些中心與本地化的製造和分銷能力相結合，支撐著相對靈活的供應鏈，能夠滿足日常需求。然而，不同司法管轄區的物流限制和監管差異仍然會為跨境計劃帶來複雜性，因此提前規劃對於避免延誤至關重要。

企業策略和競爭行為揭示了在 Carbon 13 生態系統中，投資、品質保證和夥伴關係模式正在創造永續競爭優勢的領域。

在碳-13價值鏈中佔據領先地位的企業，面臨著由產品品質、合規能力以及與終端用戶場所的接近性等因素決定的激烈競爭。許多公司正在投資擴大高純度生產線，並實施更完善的可追溯性系統，以滿足臨床和診斷客戶的文件要求。同時，與學術實驗室和臨床研究機構建立策略合作夥伴關係也日益普遍，從而能夠共同開發標記化合物和特定應用配方，進而加速碳-13的應用推廣。

經營團隊和採購人員採取以行動為導向、優先考慮的措施，以增強供應韌性，使技術規範與監管要求保持一致，並加快碳-13應用的可靠部署。

產業領導者應採取多層次策略，從碳-13應用中挖掘策略價值，同時降低供應中斷風險。首先，應拓寬供應商選擇標準，納入符合嚴格品質標準的區域製造商和替代生產商。這將減少對單一供應商的依賴，並在主要供應管道受限時縮短回應時間。其次，應在採購流程和實驗設計中實施以純度為導向的規格把關，明確產品特性與應用風險狀況和監管要求相匹配，從而避免代價高昂的後期修改。

高度透明的研究途徑，明確概述了與關鍵專家的諮詢、實驗室檢驗、監管審查和三角分析，以獲得關於碳-13的可靠見解。

支持這些發現的研究結合了與關鍵相關人員的定性對話、實驗室層面的檢驗以及文件分析，以確保多角度的觀點。研究人員採訪了技術負責人、採購專家和監管顧問，以了解營運挑戰、認證流程以及應對貿易和關稅趨勢的策略措施。實驗室檢驗活動包括對同位素純度對代表性分析方法的影響進行可重複性檢驗，以及檢驗不同產品規格相關的功能性影響。

整合關鍵策略和營運要點，強調技術協調、區域策略和適應性採購如何定義韌性和採用路徑。

整體而言，三大現實凸顯出來：技術特性的重要性、區域策略對營運存取的影響，以及透過適應性商業模式降低政策衝擊主導的風險。高純度要求和應用主導的需求需要嚴格的合格和文件編制流程，而製造、監管和物流方面的區域差異則影響企業採購決策的優先順序。此外，政策變化和貿易措施凸顯了供應商多元化和擴大國內產能作為長期韌性措施的價值。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：依純度分類的碳-13市場

  • 低於99%
  • 超過99%

第9章：碳-13市場：依應用領域分類

  • 環境調查
  • 磁振造影
  • 醫學診斷
  • 核磁共振（NMR）波譜

第10章：碳-13市場：依最終用戶分類

  • 學術機構和研究機構
  • 化學和材料工業
  • 環保組織
  • 醫療/診斷
  • 製藥/生物技術

第11章：碳-13市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第12章 碳-13市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章 碳-13市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章：美國碳-13市場

第15章：中國碳13市場

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Air Liquide SA
  • Alsachim
  • Avanti Polar Lipids, Inc.
  • BuyIsotope
  • Cambridge Isotope Laboratories, Inc.
  • CK Isotopes Ltd.
  • Eurisotop SA
  • IBA Molecular North America, Inc.
  • Isoflex USA
  • IsoPrime Limited
  • Isotec
  • LGC Standards
  • Linde PLC
  • Medical & Research Chemical Suppliers
  • Nordion, Inc.
  • Oakwood Chemical, Inc.
  • Qmx Laboratories Ltd.
  • Rotem Industries Ltd.
  • Sciex
  • Sercon Limited
  • Shanghai Chemical Industry Research Institute Co., Ltd.
  • Sigma-Aldrich Chemicals LLC
  • Thermo Fisher Scientific Inc.
  • Trace Sciences International, Inc.
  • URENCO Limited
Product Code: MRR-BF4AC2B6EEF8

The Carbon-13 Market was valued at USD 39.42 million in 2025 and is projected to grow to USD 44.15 million in 2026, with a CAGR of 7.05%, reaching USD 63.53 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 39.42 million
Estimated Year [2026] USD 44.15 million
Forecast Year [2032] USD 63.53 million
CAGR (%) 7.05%

A concise orientation explaining the strategic importance of Carbon-13 across analytical, clinical, and industrial applications and why organizations must realign sourcing and R&D priorities

Carbon-13 plays a pivotal role across analytical science, clinical research, and industrial monitoring, serving as an essential stable isotope for spectroscopy, imaging, and tracer studies. As laboratories and clinics broaden the application scope for enriched isotopes, the importance of understanding supply characteristics, purity specifications, and application-driven requirements has become a strategic priority for procurement leaders and technical teams. The isotope's unique nuclear properties enable high-resolution nuclear magnetic resonance studies, targeted metabolic imaging in clinical trials, and sensitive environmental tracking, which collectively demand a nuanced approach to sourcing and quality assurance.

Given the growing diversity of end uses, stakeholders must reevaluate their research priorities and procurement frameworks to ensure continuity of supply and compliance with evolving quality standards. In parallel, technical teams must align experimental designs with available isotope specifications to preserve reproducibility and regulatory integrity. Consequently, a clear understanding of operational constraints, supply pathways, and purity-driven performance characteristics will enable organizations to translate laboratory capability into applied outcomes without compromising timeliness or technical fidelity.

How technological advances, regulatory refinement, and cross-sector collaboration are jointly redefining supply, quality expectations, and innovation pathways for Carbon-13 applications

Recent years have seen a confluence of technological advancement, regulatory refinement, and cross-disciplinary adoption that is transforming the Carbon-13 landscape. Breakthroughs in enrichment techniques and labeling chemistries have improved product specificity and expanded feasible use cases, thus reshaping demand profiles across research and clinical communities. At the same time, regulators and institutional review boards have intensified scrutiny on clinical-grade materials and traceability, prompting suppliers to adopt more rigorous documentation and quality management practices.

Furthermore, the diffusion of advanced spectroscopic methods and metabolic imaging has created new points of intersection between academic research and commercial development. This dynamic has incentivized closer collaboration between manufacturers and end users, resulting in co-development agreements and application-focused product lines. In parallel, sustainability considerations and supply-chain resilience efforts are encouraging investment in domestic capabilities and strategic partnerships, which is changing how organizations distribute risk across geographies. As a result, industry participants now navigate a landscape where technical capability, regulatory preparedness, and strategic partnerships jointly determine competitive differentiation.

Assessing the cascading operational, procurement, and supply chain consequences of the United States tariff changes introduced in 2025 and the strategic responses they have prompted

The tariff adjustments introduced in the United States in 2025 have produced a range of operational and strategic effects that require deliberate response from stakeholders across the Carbon-13 value chain. In the immediate term, sourcing strategies shifted as procurement teams reassessed supplier portfolios to manage elevated landed costs and compliance complexity. Consequently, organizations accelerated qualification of alternative suppliers, prioritized long-term contracts with stable counterparties, and increased scrutiny of total cost of ownership to preserve budgetary predictability.

Over time, the tariffs catalyzed more structural responses within the supply base. Some suppliers accelerated investment in localized production capacity or regional partnerships to mitigate tariff exposure and shorten lead times. These moves improved logistical resilience, albeit with transitional costs related to capital deployment and workforce development. Additionally, the regulatory burden associated with cross-border shipments prompted greater investment in documentation systems and customs planning, which contributed to increased administrative overhead for both manufacturers and end users. Taken together, the tariff environment of 2025 encouraged a rebalancing of risk across sourcing networks, fostering a stronger emphasis on supplier diversification, domestic capacity building, and contractual protections that explicitly address tariff-related contingencies.

Actionable segmentation intelligence that clarifies how purity thresholds and application-specific requirements drive sourcing decisions, qualification protocols, and technical performance expectations

Segmentation provides essential context for interpreting demand drivers and technical requirements within the Carbon-13 ecosystem. Based on purity level, market analysis distinguishes between products specified as Less than 99% and those specified as More than 99%, and this distinction matters because high-purity materials are typically required for high-sensitivity analytical methods and regulatory-compliant clinical workflows. As a result, procurement teams for laboratories and clinical sites often enforce stringent qualification protocols when More than 99% purity is required, whereas research environments may accept Less than 99% material for exploratory assays where cost-efficiency is prioritized.

Equally important is segmentation by application, where supply requirements and quality expectations vary across Environmental Research, Magnetic Resonance Imaging, Medical Diagnostics, and Nuclear Magnetic Resonance (NMR) Spectroscopy. Environmental Research deployments prioritize tracer stability and matrix compatibility to ensure reliable field measurements, while Magnetic Resonance Imaging applications require materials that meet clinical-grade traceability and sterility standards. Medical Diagnostics demand both robust quality systems and batch-level documentation to satisfy regulatory pathways, and NMR Spectroscopy depends on consistent isotopic enrichment and minimal contamination to deliver reproducible spectral resolution. Consequently, aligning product specifications with application-specific requirements is central to reducing technical risk and delivering reliable results across end uses.

Regional dynamics and operational realities that determine supply resilience, regulatory alignment, and partnership strategies across the Americas, Europe, Middle East & Africa, and Asia-Pacific

Regional dynamics shape how organizations secure supply, manage logistics, and engage with regulatory frameworks. In the Americas, established research institutions and clinical networks create concentrated demand pockets, which, in tandem with localized manufacturing and distribution capabilities, support relatively responsive supply chains for routine needs. However, logistical constraints and regulatory variability across jurisdictions can still introduce complexity for cross-border projects, and proactive planning is essential to avoid delays.

Europe, Middle East & Africa presents a heterogeneous environment where regulatory harmonization efforts coexist with distinct national frameworks; as a result, suppliers and end users must invest in documentation and quality alignment to ensure market access. Collaborative networks between academic centers and industrial partners in this region often drive innovation, although fragmentation in logistics can affect lead times. In Asia-Pacific, rapid expansion of clinical research capacity and manufacturing competence has increased regional supply options, yet differences in standards and export controls require careful adjudication when establishing long-term procurement relationships. Across all regions, strategic partnerships, regional manufacturing footprints, and tailored regulatory strategies determine the extent to which organizations can achieve resilient and cost-effective supply continuity.

Corporate strategies and competitive behaviors that reveal where investment, quality assurance, and partnership models are creating durable advantages in the Carbon-13 ecosystem

Leading organizations in the Carbon-13 value chain are navigating a competitive environment defined by product quality, regulatory competence, and proximity to end-use centers. Many firms are directing capital toward expanding high-purity production lines and implementing enhanced traceability systems to meet the documentation demands of clinical and diagnostic customers. Concurrently, strategic collaborations with academic laboratories and clinical research organizations are increasingly common, enabling co-development of labeled compounds and application-specific formulations that accelerate adoption.

Market participants are also optimizing commercial models through flexible contracting, including long-term supply agreements and inventory consignment arrangements that stabilize availability for high-priority programs. Quality management and certification remain key differentiators, as they reduce technical barriers for customers entering regulated use cases. In addition, several companies prioritize process innovation to increase yield and reduce impurity profiles, thereby improving product competitiveness without relying solely on price. Overall, successful corporate strategies combine technical excellence with downstream-facing services that support customer validation and application deployment.

Practical, prioritized actions for executives and procurement leaders to fortify supply resilience, align technical specifications with regulatory needs, and accelerate reliable adoption of Carbon-13 applications

Industry leaders should adopt a layered approach to mitigate disruption while unlocking strategic value from Carbon-13 applications. Begin by broadening supplier qualification criteria to include regional manufacturers and alternate producers that can meet rigorous quality standards; this reduces single-source exposure and shortens response time when primary channels are constrained. Next, incorporate purity-driven specification gates into procurement and experimental design so that the team explicitly matches product attributes to application risk profiles and regulatory needs, thereby avoiding costly downstream remediation.

In parallel, invest in contractual provisions that address tariff volatility, including clauses for cost-sharing, allocation, and advance notice periods, which can preserve budget certainty and commercial relationships. Additionally, prioritize partnerships with academic and clinical centers to co-develop application-specific solutions that accelerate time-to-result and reduce internal development burden. Finally, allocate resources to strengthen traceability and quality systems so that clinical, diagnostic, and regulatory stakeholders receive consistent documentation and batch-level assurances; this not only mitigates compliance risk but also enhances credibility with downstream partners and payers.

A transparent research approach describing primary expert engagement, laboratory validation, regulatory review, and triangulated analysis used to generate reliable insights on Carbon-13

The research underpinning these insights combined primary qualitative engagement, laboratory-level validation, and documentary analysis to ensure a multifaceted perspective. Interviews were conducted with technical leads, procurement specialists, and regulatory advisors to capture operational pain points, qualification processes, and strategic responses to trade and tariff dynamics. Laboratory validation activities included reproducibility checks of isotopic purity effects on representative analytical methods to verify the functional consequences associated with different product specifications.

Documentary analysis encompassed a review of regulatory guidance, shipping and customs requirements, and publicly disclosed quality standards to map compliance risk factors and identify best practices. Findings were triangulated across sources to ensure consistency and to reconcile divergent perspectives between suppliers and end users. Where applicable, supply chain mappings were stress-tested against hypothetical disruption scenarios to derive practical mitigation strategies. This combination of methods produced a robust evidence base that supports reproducible conclusions and practical recommendations for stakeholders across the value chain.

Synthesis of the critical strategic and operational takeaways that underscore why technical alignment, regional strategy, and adaptive sourcing define resilience and adoption pathways

In aggregate, the evidence highlights three enduring realities: technical specificity matters, regional strategy influences operational access, and adaptive commercial models reduce exposure to policy-driven shocks. High-purity requirements and application-driven demands necessitate rigorous qualification and documentation practices, while regional differences in manufacturing, regulation, and logistics shape how organizations prioritize sourcing decisions. Moreover, policy shifts and trade measures have underscored the value of supplier diversification and domestic capacity expansion as long-term resilience measures.

Consequently, organizations that combine technical rigor with strategic sourcing, contractual foresight, and collaborative development will be best positioned to harness Carbon-13 for research, clinical, and environmental applications. By operationalizing the recommendations presented, stakeholders can reduce technical risk, strengthen supply continuity, and accelerate the translation of analytical capability into actionable outcomes for science and patient care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Carbon-13 Market, by Purity Level

  • 8.1. Less than 99%
  • 8.2. More than 99%

9. Carbon-13 Market, by Application

  • 9.1. Environmental Research
  • 9.2. Magnetic Resonance Imaging
  • 9.3. Medical Diagnostics
  • 9.4. Nuclear Magnetic Resonance (NMR) Spectroscopy

10. Carbon-13 Market, by End-User

  • 10.1. Academia & Research Institutions
  • 10.2. Chemicals / Materials Industry
  • 10.3. Environmental Agencies
  • 10.4. Healthcare / Diagnostics
  • 10.5. Pharmaceutical / Biotechnology

11. Carbon-13 Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Carbon-13 Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Carbon-13 Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. United States Carbon-13 Market

15. China Carbon-13 Market

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025
  • 16.5. Air Liquide S.A.
  • 16.6. Alsachim
  • 16.7. Avanti Polar Lipids, Inc.
  • 16.8. BuyIsotope
  • 16.9. Cambridge Isotope Laboratories, Inc.
  • 16.10. CK Isotopes Ltd.
  • 16.11. Eurisotop SA
  • 16.12. IBA Molecular North America, Inc.
  • 16.13. Isoflex USA
  • 16.14. IsoPrime Limited
  • 16.15. Isotec
  • 16.16. LGC Standards
  • 16.17. Linde PLC
  • 16.18. Medical & Research Chemical Suppliers
  • 16.19. Nordion, Inc.
  • 16.20. Oakwood Chemical, Inc.
  • 16.21. Qmx Laboratories Ltd.
  • 16.22. Rotem Industries Ltd.
  • 16.23. Sciex
  • 16.24. Sercon Limited
  • 16.25. Shanghai Chemical Industry Research Institute Co., Ltd.
  • 16.26. Sigma-Aldrich Chemicals LLC
  • 16.27. Thermo Fisher Scientific Inc.
  • 16.28. Trace Sciences International, Inc.
  • 16.29. URENCO Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL CARBON-13 MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CARBON-13 MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL CARBON-13 MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL CARBON-13 MARKET SIZE, BY PURITY LEVEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL CARBON-13 MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CARBON-13 MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL CARBON-13 MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CARBON-13 MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL CARBON-13 MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. UNITED STATES CARBON-13 MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 11. CHINA CARBON-13 MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL CARBON-13 MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL CARBON-13 MARKET SIZE, BY PURITY LEVEL, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL CARBON-13 MARKET SIZE, BY LESS THAN 99%, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL CARBON-13 MARKET SIZE, BY LESS THAN 99%, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL CARBON-13 MARKET SIZE, BY LESS THAN 99%, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL CARBON-13 MARKET SIZE, BY MORE THAN 99%, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL CARBON-13 MARKET SIZE, BY MORE THAN 99%, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL CARBON-13 MARKET SIZE, BY MORE THAN 99%, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL CARBON-13 MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CARBON-13 MARKET SIZE, BY ENVIRONMENTAL RESEARCH, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CARBON-13 MARKET SIZE, BY ENVIRONMENTAL RESEARCH, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CARBON-13 MARKET SIZE, BY ENVIRONMENTAL RESEARCH, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL CARBON-13 MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL CARBON-13 MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL CARBON-13 MARKET SIZE, BY MAGNETIC RESONANCE IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL CARBON-13 MARKET SIZE, BY MEDICAL DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL CARBON-13 MARKET SIZE, BY MEDICAL DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL CARBON-13 MARKET SIZE, BY MEDICAL DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL CARBON-13 MARKET SIZE, BY NUCLEAR MAGNETIC RESONANCE (NMR) SPECTROSCOPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL CARBON-13 MARKET SIZE, BY NUCLEAR MAGNETIC RESONANCE (NMR) SPECTROSCOPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL CARBON-13 MARKET SIZE, BY NUCLEAR MAGNETIC RESONANCE (NMR) SPECTROSCOPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL CARBON-13 MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL CARBON-13 MARKET SIZE, BY ACADEMIA & RESEARCH INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL CARBON-13 MARKET SIZE, BY ACADEMIA & RESEARCH INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL CARBON-13 MARKET SIZE, BY ACADEMIA & RESEARCH INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL CARBON-13 MARKET SIZE, BY CHEMICALS / MATERIALS INDUSTRY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL CARBON-13 MARKET SIZE, BY CHEMICALS / MATERIALS INDUSTRY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL CARBON-13 MARKET SIZE, BY CHEMICALS / MATERIALS INDUSTRY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL CARBON-13 MARKET SIZE, BY ENVIRONMENTAL AGENCIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL CARBON-13 MARKET SIZE, BY ENVIRONMENTAL AGENCIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL CARBON-13 MARKET SIZE, BY ENVIRONMENTAL AGENCIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL CARBON-13 MARKET SIZE, BY HEALTHCARE / DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CARBON-13 MARKET SIZE, BY HEALTHCARE / DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CARBON-13 MARKET SIZE, BY HEALTHCARE / DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CARBON-13 MARKET SIZE, BY PHARMACEUTICAL / BIOTECHNOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL CARBON-13 MARKET SIZE, BY PHARMACEUTICAL / BIOTECHNOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL CARBON-13 MARKET SIZE, BY PHARMACEUTICAL / BIOTECHNOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL CARBON-13 MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. AMERICAS CARBON-13 MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 40. AMERICAS CARBON-13 MARKET SIZE, BY PURITY LEVEL, 2018-2032 (USD MILLION)
  • TABLE 41. AMERICAS CARBON-13 MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 42. AMERICAS CARBON-13 MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 43. NORTH AMERICA CARBON-13 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. NORTH AMERICA CARBON-13 MARKET SIZE, BY PURITY LEVEL, 2018-2032 (USD MILLION)
  • TABLE 45. NORTH AMERICA CARBON-13 MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 46. NORTH AMERICA CARBON-13 MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 47. LATIN AMERICA CARBON-13 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. LATIN AMERICA CARBON-13 MARKET SIZE, BY PURITY LEVEL, 2018-2032 (USD MILLION)
  • TABLE 49. LATIN AMERICA CARBON-13 MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 50. LATIN AMERICA CARBON-13 MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 51. EUROPE, MIDDLE EAST & AFRICA CARBON-13 MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 52. EUROPE, MIDDLE EAST & AFRICA CARBON-13 MARKET SIZE, BY PURITY LEVEL, 2018-2032 (USD MILLION)
  • TABLE 53. EUROPE, MIDDLE EAST & AFRICA CARBON-13 MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 54. EUROPE, MIDDLE EAST & AFRICA CARBON-13 MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 55. EUROPE CARBON-13 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. EUROPE CARBON-13 MARKET SIZE, BY PURITY LEVEL, 2018-2032 (USD MILLION)
  • TABLE 57. EUROPE CARBON-13 MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 58. EUROPE CARBON-13 MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 59. MIDDLE EAST CARBON-13 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. MIDDLE EAST CARBON-13 MARKET SIZE, BY PURITY LEVEL, 2018-2032 (USD MILLION)
  • TABLE 61. MIDDLE EAST CARBON-13 MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 62. MIDDLE EAST CARBON-13 MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 63. AFRICA CARBON-13 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. AFRICA CARBON-13 MARKET SIZE, BY PURITY LEVEL, 2018-2032 (USD MILLION)
  • TABLE 65. AFRICA CARBON-13 MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 66. AFRICA CARBON-13 MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 67. ASIA-PACIFIC CARBON-13 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC CARBON-13 MARKET SIZE, BY PURITY LEVEL, 2018-2032 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC CARBON-13 MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC CARBON-13 MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL CARBON-13 MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. ASEAN CARBON-13 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. ASEAN CARBON-13 MARKET SIZE, BY PURITY LEVEL, 2018-2032 (USD MILLION)
  • TABLE 74. ASEAN CARBON-13 MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 75. ASEAN CARBON-13 MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 76. GCC CARBON-13 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GCC CARBON-13 MARKET SIZE, BY PURITY LEVEL, 2018-2032 (USD MILLION)
  • TABLE 78. GCC CARBON-13 MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 79. GCC CARBON-13 MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPEAN UNION CARBON-13 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPEAN UNION CARBON-13 MARKET SIZE, BY PURITY LEVEL, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPEAN UNION CARBON-13 MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPEAN UNION CARBON-13 MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 84. BRICS CARBON-13 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 85. BRICS CARBON-13 MARKET SIZE, BY PURITY LEVEL, 2018-2032 (USD MILLION)
  • TABLE 86. BRICS CARBON-13 MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 87. BRICS CARBON-13 MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 88. G7 CARBON-13 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. G7 CARBON-13 MARKET SIZE, BY PURITY LEVEL, 2018-2032 (USD MILLION)
  • TABLE 90. G7 CARBON-13 MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 91. G7 CARBON-13 MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 92. NATO CARBON-13 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 93. NATO CARBON-13 MARKET SIZE, BY PURITY LEVEL, 2018-2032 (USD MILLION)
  • TABLE 94. NATO CARBON-13 MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 95. NATO CARBON-13 MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL CARBON-13 MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 97. UNITED STATES CARBON-13 MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 98. UNITED STATES CARBON-13 MARKET SIZE, BY PURITY LEVEL, 2018-2032 (USD MILLION)
  • TABLE 99. UNITED STATES CARBON-13 MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 100. UNITED STATES CARBON-13 MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 101. CHINA CARBON-13 MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 102. CHINA CARBON-13 MARKET SIZE, BY PURITY LEVEL, 2018-2032 (USD MILLION)
  • TABLE 103. CHINA CARBON-13 MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 104. CHINA CARBON-13 MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)